30 Mar Complix to Present at AACR 2017
Hasselt, March 30, 2016 – Complix, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, announces that its research team will be presenting their most recent data on anti-MCL-1 Alphabodies at the American Association for Cancer Research meeting in Washington, D.C., April 1-5. The poster entitled “Cell penetrating proteins targeting Mcl-1 induce in vitro and in vivo on-target cancer cell killing of Mcl-1 dependent cell lines” will provide insight in the recent progress that the Complix team has achieved in developing cell penetrating Alphabodies (CPABs) that act on an important intracellular cancer target and provoke on-target effects in vivo.
Details of the poster presentation are as follows:
- Title of the poster: “Cell penetrating proteins targeting Mcl-1 induce in vitro and in vivo on-target cancer cell killing of Mcl-1 dependent cell lines.”
- Poster section: 2, poster number 28 (poster board number 9)
- Time: 2nd of April between 1 and 5 PM
Complix is a biopharmaceutical company developing a pipeline of novel biotherapeutics, called Alphabodies™, mainly focused on oncology and autoimmune diseases.
Alphabodies are a revolutionary class of protein therapeutics that have the potential to address a wide range of disease targets, in particular intracellular targets that are considered undruggable by current drug formats, such as antibodies or small chemicals.
Complix is building a portfolio of Alphabody based therapeutics that act on a variety of intractable intracellular targets and is working in collaboration with pharma companies to create novel first-in-class therapeutics that have the potential to cure severe diseases with high medical need, including cancer. In December 2015 Complix signed a strategic collaboration with Merck & Co to develop novel Alphabody based therapeutics against two intracellular cancer targets. Under the terms of this deal Complix will be eligible to receive up to $280 million in upfront and development and regulatory milestones as well as tiered mid-single digit royalties on global sales revenues.
Complix NV (Belgium) and its affiliate Complix SA (Luxembourg) have established a strong intellectual property position protecting the Alphabody™ platform and its emerging product portfolio through the filing of multiple broad patent applications. Since its founding in 2008 Complix has raised a total of more than €20 million in venture financing, including a €12 million B round in June 2013 and a €7 million Series A equity round in 2010.
Dr. Yvonne McGrath, CSO
Tel. +32 9 261 69 40